Transmedics Group Inc (NASDAQ: TMDX) has experienced a rise in its stock price by 6.54 compared to its previous closing price of 64.35. However, the company has seen a gain of 1.63% in its stock price over the last five trading days. accessnewswire.com reported 2025-03-14 that NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=136089&wire=1 or contact Joseph E. Levi, Esq.
Is It Worth Investing in Transmedics Group Inc (NASDAQ: TMDX) Right Now?
Transmedics Group Inc (NASDAQ: TMDX) has a higher price-to-earnings ratio of 67.87x compared to its average ratio, The 36-month beta value for TMDX is at 2.14. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for TMDX is 32.43M, and currently, shorts hold a 28.77% of that float. The average trading volume for TMDX on March 14, 2025 was 1.84M shares.
TMDX’s Market Performance
TMDX stock saw a decrease of 1.63% in the past week, with a monthly decline of -1.38% and a quarterly a decrease of -0.62%. The volatility ratio for the week is 6.24%, and the volatility levels for the last 30 days are 6.82% for Transmedics Group Inc (TMDX). The simple moving average for the past 20 days is -3.34% for TMDX’s stock, with a -38.86% simple moving average for the past 200 days.
Analysts’ Opinion of TMDX
Many brokerage firms have already submitted their reports for TMDX stocks, with JP Morgan repeating the rating for TMDX by listing it as a “Neutral.” The predicted price for TMDX in the upcoming period, according to JP Morgan is $75 based on the research report published on December 17, 2024 of the previous year 2024.
Oppenheimer gave a rating of “Outperform” to TMDX, setting the target price at $125 in the report published on October 29th of the previous year.
TMDX Trading at 0.08% from the 50-Day Moving Average
After a stumble in the market that brought TMDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.35% of loss for the given period.
Volatility was left at 6.82%, however, over the last 30 days, the volatility rate increased by 6.24%, as shares sank -5.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.09% upper at present.
During the last 5 trading sessions, TMDX rose by +0.25%, which changed the moving average for the period of 200-days by -51.79% in comparison to the 20-day moving average, which settled at $70.89. In addition, Transmedics Group Inc saw 9.96% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMDX starting from Khayal Tamer I, who sale 2,407 shares at the price of $76.43 back on Mar 03 ’25. After this action, Khayal Tamer I now owns 36,042 shares of Transmedics Group Inc, valued at $183,967 using the latest closing price.
Gordon Stephen, the Officer of Transmedics Group Inc, proposed sale 5,942 shares at $65.61 during a trade that took place back on Mar 04 ’25, which means that Gordon Stephen is holding shares at $389,855 based on the most recent closing price.
Stock Fundamentals for TMDX
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.59 for the gross margin
The net margin for Transmedics Group Inc stands at 0.08. The total capital return value is set at 0.05. Equity return is now at value 19.39, with 4.70 for asset returns.
Based on Transmedics Group Inc (TMDX), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at 0.11. The debt to equity ratio resting at 2.01. The interest coverage ratio of the stock is 3.47.
Currently, EBITDA for the company is 69.95 million with net debt to EBITDA at 1.93. When we switch over and look at the enterprise to sales, we see a ratio of 5.49. The receivables turnover for the company is 4.52for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.30.
Conclusion
In conclusion, Transmedics Group Inc (TMDX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
